Ask AI

Capsule Summaries

Share

Program Content

Activities

  • INCA033989 in ET
    Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2025

  • IMerge Post Hoc Analysis
    IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2025

  • VERONA Subgroup Analyses
    VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2025

  • INCA033989 in MF
    Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2025

  • MANIFEST 2 96 Wk Update
    MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MF
    Case Challenge
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2025

  • Reduced Duration HMA in LR MDS
    Randomized Phase II Trial of Reduced Treatment Durations With Hypomethylating Agents in Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner